CASE REPORT article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
This article is part of the Research TopicExploring Cutaneous Drug-Related and Drug-Associated Adverse Events: From Clinical Insight to Therapeutic ManagementView all 12 articles
Case Report: Pembrolizumab associated lichen planus in early stage triple negative breast cancer
Provisionally accepted
- 1Department of Medical Oncology, Faculty of Medicine, Ondokuz Mayıs University, Samsun, Türkiye
- 2Department of Pathology, Faculty of Medicine, Ondokuz Mayıs University, Samsun, Türkiye
- 3Department of Dermatology, Ondokuz Mayis Universitesi Tip Fakultesi, Samsun, Türkiye
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract Triple negative breast cancer (TNBC) is a breast cancer with a poor prognosis, marked by the absence of estrogen (ER) and progesterone (PR) receptors as well as human epidermal growth factor receptor (HER2) expression. Although TNBC is characterized by a high recurrence rate and poorer survival, it is more sensitive to chemotherapy compared to other breast cancer subtypes. The use of targeted immunotherapy approaches has been brought to the agenda for the treatment of both early and advanced TNBC, as TNBCs are immunogenic active tumors. In systemic therapy, addition of immune checkpoint inhibitors to cytotoxic chemotherapy is used as part of the neoadjuvant treatment approach. Pembrolizumab is a monoclonal antibody that blocks the interaction between the programmed death-ligand 1 (PD-L1) receptor on T cells and the PD-L1 and PD-L2 ligands on tumor cells. It has been shown to be effective in TNBC, melanoma, lung cancer and other advanced solid tumors and hematologic malignancies. Several skin-related side effects have been documented, such as pruritus, maculopapular rashes, vitiligo, lichenoid skin reactions, psoriasis, and, in rare cases, severe and potentially life-threatening conditions. We report a rare case of pembrolizumab-associated lichen planus in a 43-year-old woman who received pembrolizumab for neoadjuvant treatment of TNBC.
Keywords: breast cancer, Immune-related side effects, Immunotherapy, Lichen Planus, Pembrolizumab
Received: 15 Oct 2025; Accepted: 12 Dec 2025.
Copyright: © 2025 Buyukahisha, ozcelik, baycelebi, cakir and cetin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ozge Buyukahisha
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.